Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2006-002257-76
    Sponsor's Protocol Code Number:3074K5-319-WW
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2007-10-09
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2006-002257-76
    A.3Full title of the trial
    A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once Daily Dose of Tigecycline versus Ertapenem for the Treatment of Foot Infections in Subjects with Diabetes
    STUDIO MULTICENTRICO, RANDOMIZZATO, DOPPIO CIECO, COMPARATIVO DELLA SICUREZZA E DELL’EFFICACIA DI UNA DOSE GIORNALIERA DI TIGECICLINA VERSO ERTAPENEM PER IL TRATTAMENTO DELLE INFEZIONI DEL PIEDE IN SOGGETTI CON DIABETE.
    A.4.1Sponsor's protocol code number3074K5-319-WW
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorWyeth Research Division of Wyeth Pharmaceuticals Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Tygacil 50 mg powder for solution for infusion
    D.2.1.1.2Name of the Marketing Authorisation holderWyeth Europa Ltd.
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntracavernous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTIGECYCLINE
    D.3.9.1CAS number 220620-09-7
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeNon Applicabile
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name INVANZ 1 g powder for concentrate for solution for infusion
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Sharp & Dohme Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNERTAPENEM SDODIUM
    D.3.10 Strength
    D.3.10.1Concentration unit % percent
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeNon Applicabile
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Subjects with diabetes and a qualifying foot infection
    Soggetti con diabete ed una adeguata infezione del piede.
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.0
    E.1.2Level PT
    E.1.2Classification code 10060803
    E.1.2Term Diabetic foot infection
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the relative safety and clinical efficacy of a once-daily dose of tigecycline versus ertapenem in the treatment of subjects with diabetic foot infections.
    Confrontare la relativa sicurezza e l’efficacia clinica di una dose giornaliera di tigeciclina verso ertapenem nel trattamento dei soggetti con infezioni del piede diabetico.
    E.2.2Secondary objectives of the trial
    1) To evaluate the microbiologic efficacy of tigecycline; 2) To obtain in vitro susceptibility data on tigecycline for a range of bacterial pathogens isolated from diabetic foot infections; 3) To compare health care resource utilization between treatment arms; 4) To examine the pharmacokinetic profile of tigecycline in subjects with diabetic foot infections after once daily administration and after prolonged administration; and 5) To evaluate the safety and efficacy of a once-daily dose of tigecycline in the treatment of subjects who are identified as having a diabetic foot infection with confirmed osteomyelitis.
    1) Valutare l’efficacia microbiologica di tigeciclina; 2) Ottenere i dati di sensibilita' in vitro di tigeciclina per un range di batteri patogeni isolati da infezioni del piede diabetico; 3) Confrontare l’utilizzazione delle risorse sanitarie tra i due bracci del trattamento; 4) Esaminare il profilo farmacocinetico di tigeciclina nei soggetti con infezioni del piede diabetico dopo una somministrazione giornaliera e dopo una somministrazione prolungata; e 5) Valutare la sicurezza e l’efficacia di una somministrazione giornaliera di tigeciclina nel trattamento dei soggetti con infezioni del piede diabetico con osteomielite confermata.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Hospitalized male or female subjects ³ 18 years of age.
    2. Subjects with diabetes mellitus per the American Diabetes Association (ADA) criteria.
    3. Subjects with a foot infection that does not extend above the knee. If multiple infections meet all criteria below, the one with the highest IWGDF PEDIS grade for infection will be designated as the target.
    4. Subjects with a foot infection that meets all of the following IWGDF PEDIS classifications (note: an ulcer is not required):
    · Perfusion: grade 1 or 2;
    · Infection: grades 2 to 4.
    5. Subjects with anticipated need for IV antibiotic therapy of 5 days or longer.
    6. Subjects whose foot infection has had an acute onset or worsening of signs and symptoms within the past 14 days.
    7. Subjects who have received £ 48 hours administration of a potentially effective antibiotic (ie, active against all pathogens known to be present) to treat the current target infection.
    8. Subjects who are considered to be therapeutic failures of prior antibiotic therapy with another agent may be enrolled if they have had worsening or no improvement in the clinical signs and symptoms of their diabetic foot infection and either have 1) a Gram stain from the infection site showing white blood cells and a potential pathogen or 2) culture results showing a pathogen resistant to prior antibiotics. Note: Subject may not have failed one of the study medications or any agent of the same class.
    9. Osteomyelitis substudy arm only: Subjects who have presumptive evidence of osteomyelitis, defined as visible bone, a positive radiograph (ie, demineralization, periosteal reaction, and bony destruction), or a positive probe-to-bone finding (as described by Grayson et al). [Attachment 2] or confirmed evidence of osteomyelitis, defined as positive MRI (eg, decreased marrow signal on T1-weighted images, increased marrow signal on T2 weighted images, and contrast enhancement on T1-weighted post-contrast images) or positive bone biopsy.
    1.Maschi e femmine ospedalizzati di 18 o piu' anni. 2.Soggetti con diabete mellito come da criteri dell’American Diabetes Association (ADA).24 3.Soggetti con un’infezione del piede che non si estende sopra il ginocchio. Se infezioni multiple incontrano tutti i criteri sotto indicate, quella con il piu' alto grado di IWGDF PEDIS per infezione, sara' designata come target. 4.Soggetti con un’infezione del piede che incontra tutte le seguenti classificazioni della IWGDF PEDIS (nota: non e' richiesta un’ulcera): ·Perfusione: grado 1 o 2; ·Infezione: gradi dal 2 al 4. 5.Soggetti con un previsto bisogno di terapia antibiotica IV di 5 o piu' giorni. 6.Soggetti la cui infezione del piede ha avuto un inizio acuto o un peggioramento dei segni e dei sintomi negli ultimi 14 giorni. 7.Soggetti che hanno ricevuto una somministrazione &lt; o = 48 ore di un antibiotico potenzialmente efficace (cioe' attivo contro tutti i patogeni conosciuti presenti) per trattare l’attuale infezione target. 8.Soggetti che sono considerati come fallimento terapeutico della precedente terapia antibiotica con un altro agente, possono essere arruolati se hanno avuto un peggioramento o nessun miglioramento nei segni e nei sintomi clinici dell’infezione del loro piede diabetico e hanno anche 1) una colorazione di Gram dal sito dell’infezione che mostra cellule bianche del sangue e un potenziale patogeno, o 2) risultati di una coltura mostrano patogeni resistenti ai precedenti antibiotici. Nota: Il soggetto potrebbe non aver fallito uno dei farmaci in studio o un agente della stessa classe. 9. Solo per il braccio del sottostudio dell’ Osteomielite: Soggetti con una presunta evidenza di osteomielite, definita come un osso visibile, una radiografia positiva (cioe', demineralizzazione, reazione periostea, e distruzione ossea),o una positivita' al test dell’osso (come descritto da Grayson ed al.), o una confermata evidenza di osteomielite, definita come RMN positiva (es, ridotto segnale midollare sulle immagini T1-pesate, segnale midollare aumentato sulle immagini T2 pesate, ed aumento del contrasto sulle immagini post contrasto T1-pesate), o biopsia ossea positiva.
    E.4Principal exclusion criteria
    1. Necrotizing fasciitis, crepitant cellulitis, wet gangrene, gas gangrene, ecthyma gangrenosum, or severely impaired arterial supply to any portion of the affected foot.
    2. Infected prosthetic materials or devices that will not be removed.
    3. Suspected or known infection with a pathogen resistant to tigecycline or ertapenem ± vancomycin (eg, P. aeruginosa).
    4. Subjects with
    a. a diabetic foot infection without presumptive evidence of osteomyelitis (as defined above) who are anticipated to need > 28 days of antibiotic treatment. (primary study arm)
    OR
    b. a diabetic foot infection with presumptive evidence of osteomyelitis (as defined above) who are anticipated to need > 42 days of antibiotic treatment.(osteomyelitis substudy arm)
    5. Anticipated requirement for complete resection or amputation (ie, removal of all infected tissue with clean margins) of the infected anatomical site within 1 month (30 days). Note: Subjects who will have all infected bone removed, but still have a skin infection may be randomized to the primary study arm after the removal of the infected bone.
    6. Concurrent hemodialysis, hemofiltration, peritoneal dialysis or plasmapheresis.
    7. Any concomitant condition that, in the opinion of the investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy could be completed (eg, life expectancy < 30 days).
    8. Subjects with contraindication or hypersensitivity to any of the test articles or related antibiotics.
    9. Presence of any of the following laboratory findings:
    a. Neutropenia with absolute neutrophil count < 1 ´ 109/L [<1000/mm3]
    b. Presence of significant hepatic disease:
    i. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) >10 ´ the upper limit of normal (ULN);
    ii. Total bilirubin > 3 ´ the ULN;
    iii. Acute hepatic failure or acute decompensation of chronic hepatic failure.
    c. Creatinine clearance (ClCR) < 30 mL/min, Creatinine clearance may be calculated from the serum creatinine (SCR) concentration by the following equation:
    Male: ClCR mL/min = (140-age) ´ weight (kg) / (72 ´ SCR [mg/dL])
    Female: ClCR mL/min = 0.85 ´ ([140-age] ´ weight [kg] / [72 ´ SCR {mg/dL}]).
    10. Known or suspected concurrent infection that would require treatment with a systemic antibacterial agent(s).
    11. Any investigational drugs taken or investigational devices used within 4 weeks before the first dose of IV test article administration.
    12. Previous participation in this study.
    13. Pregnant or breastfeeding women.
    14. Women of childbearing potential who do not agree either to practice sexual abstinence or use a medically acceptable method of contraception throughout the duration of the study and for at least 1 month (30 days) after the last day of IV test article administration. A woman of childbearing potential is one who is biologically capable of becoming pregnant; this includes women who are using contraceptives or those women whose sexual partners are either considered sterile or using contraceptives.
    15. Subjects taking immunosuppressive therapy, defined as chronic treatment with known immunosuppressive medications (including the use of > 40 mg of prednisone or its equivalent per day for >3 weeks before randomization), or any severely immunocompromised subjects.
    1. Fascite necrotizzante, cellulite crepitante, gangrena umida, gangrena gassosa, ecthyma gangrenosum, o irrorazione arteriosa gravemente insufficiente in una parte del piede interessato.
    2. Strumenti o materiali protesici infetti, che non saranno rimossi.
    3. Infezione sospetta o conosciuta con un patogeno resistente a Tigeciclina o ertapenem ± vancomicina (es.: P. aeruginosa).
    4. Soggetti con
    a. Un’infezione del piede diabetico senza una presunta evidenza di osteomielite (come sopra definito) che necessitino di un trattamento antibiotico di piu' di 28 giorni. (braccio primario dello studio).
    O
    b. piede diabetico con una presunta evidenza di osteomielite (come sopra definito) che si prevede necessiti di un trattamento antibiotico &gt; 42 giorni (braccio del sottostudio dell’ Osteomielite)
    5. Anticipata valutazione di una resezione completa o un’amputazione (cioe', rimozione di tutto il tessuto infetto con pulizia dei margini) del sito anatomico infetto entro 1 mese (30 giorni). Nota: i soggetti cui verra' rimosso tutto l’osso infettato, ma che avranno ancora un’infezione della cute, possono essere randomizzati al braccio primario dello studio dopo la rimozione dell’osso infetto.
    6.Concomitante emodialisi, emofiltrazione, dialisi peritoneale o plasmaferesi.
    7. Ogni concomitante condizione che, a giudizio dello sperimentatore, potrebbe precludere una valutazione di una risposta o rendere improbabile il completamento del previsto corso della terapia (es.: attesa di vita &lt; 30 giorni).
    8. Soggetti con controindicazione o ipersensibilita' ad uno dei prodotti in studio o antibiotici correlati.
    9. Presenza di uno dei seguenti risultati di laboratorio:
    a. Neutropenia con conta assoluta dei neutrofili &lt; 1 ´ 109/L [&lt;1000/mm3]
    b. Presenza di una significativa patologia epatica:
    i. Aspartato aminotransferasi (AST), alanina aminotransferasi (ALT) &gt;10 ´ il limite superiore del normale (upper limit of normal: ULN);
    ii. Bilirubina totale &gt; 3 ´ l’ULN;
    iii. Insufficienza epatica acuta o acuto scompenso di un’insufficienza epatica cronica.
    c. Creatinina clearance (ClCR) &lt; 30 mL/min. La Creatinina clearance puo' essere calcolata dalla concentrazione sierica della creatinina (SCR) con la seguente equazione:
    Maschio: ClCR mL/min = (140-eta') ´ peso (kg) / (72 ´ SCR [mg/dL])
    Femmina: ClCR mL/min = 0.85 ´ ([140-eta'] ´ peso [kg] / [72 ´ SCR {mg/dL}]).
    10. Conosciuta o sospetta infezione concomitante che potrebbe richiedere un trattamento con un agente sistemico antibatterico.
    11. Un farmaco sperimentale assunto o un dispositivo sperimentale utilizzato entro 4 settimane prima della prima dose del prodotto IV in studio.
    12. Precedente partecipazione in questo studio.
    13. Donne in gravidanza o allattanti.
    14. Donne in eta' fertile che o non vogliono praticare un’astinenza sessuale o non vogliono usare un metodo contraccettivo accettabile da un punto di vista medico per il corso dello studio e per almeno 1 mese (30 giorni) dopo l’ultimo giorno della somministrazione del prodotto in studio per IV. Una donna fertile e' una donna che e' biologicamente in grado di divenire gravida; questo comprende donne che stanno usando contraccettivi o quelle donne i cui partner sessuali sono considerati o sterili o usano contraccettivi.
    15. Soggetti che assumono terapia immunosoppressiva, definite come un trattamento cronico con riconosciuta attivita' immunosoppressiva (compreso l’uso di &gt; 40 mg di prednisone o un suo equivalente al giorno per &gt;3 settimane prima della randomizzazione), o soggetti gravemente immunocompromessi.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint will be the clinical response rate at the test-of-cure (TOC) visit for 2 co-primary populations: the clinically evaluable (CE) population and the clinical modified intent-to-treat (c-mITT) population. The microbiologic responses are secondary endpoints.
    L’endpoint di efficacia primario sara' la percentuale della risposta clinica alla visita di valutazione della cura (test-of-cure: TOC) per le 2 popolazioni co-primarie: la popolazione clinicamente valutabile e la popolazione di intent-to-treat clinico modificato: (c-mITT). Le risposte microbiologiche sono gli endpoint secondari.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Information not present in EudraCT
    E.8.1.3Single blind Information not present in EudraCT
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Information not present in EudraCT
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Information not present in EudraCT
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last patient last visit
    Last patient last visit
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months20
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months20
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state40
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 300
    F.4.2.2In the whole clinical trial 950
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2007-11-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2007-09-13
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2009-03-18
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 10:34:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA